Progressive Supranuclear Palsy Clinical Trial
— Gait-PSPOfficial title:
Pathophysiology of Gait and Posture in Progressive Supranuclear Palsy
Verified date | September 2019 |
Source | Centre Hospitalier Universitaire de Pointe-a-Pitre |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The main hypothesis is that the gait and postural deficits in the Caribbean form of PSP may be associated with a dysfunction of the cerebral cortex, as they result from sub-cortical involvement in classical forms. The investigators will characterize the gait and posture with a force platform to collect biomechanical gait parameters, coupled with the kinematic and electromyographic (EMG) study. Then the investigators realize a multimodal imaging study [structural magnetic resonance imaging (MRI) and diffusion tensor imaging (DTI)] that allow us to determine if a correlation can be found between the clinical characteristics of postural control and walking on one hand, and morphological changes and structural MRI changes in cortico-subcortical pathways on the other hand. The study of performance on neuropsychological tests, registration of ocular movements and the analysis of functional cortical activity will complete our multimodal approach. A better understanding of these disorders is expected to propose new drug treatment and rehabilitative strategies.
Status | Completed |
Enrollment | 48 |
Est. completion date | July 12, 2018 |
Est. primary completion date | July 12, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 40 Years and older |
Eligibility |
Inclusion Criteria: - Patient : - Patients who met the clinical criteria for PSP and Gd-PSP - Walking and standing alone without assistance - Patient or responsible third party who received information about the study and who signed the informed consent - French - Patients over 40 years - Clinically detectable eye movement anomaly Witnesses : - To be affiliated or beneficiary of social security scheme - French person - Major subjects, matched for age (± 3 years) and sex, showing no neurological or psychiatric disease or severe progressive disease - No Indication against MRI Exclusion Criteria: Patient : - Patient not affiliated with the social security system - Cognitive impairment: MMSE = 20; FAB = 12 - psychiatric disorders likely to interfere with exploration; severe postural disorders - MRI not feasible Witnesses - Not affiliated or benificiary of social security scheme - Not a french person - Somebody showing neurological or psychiatric disease or severe progressive disease |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Centre Hospitalier Universitaire de Pointe-a-Pitre | Groupe Hospitalier Pitie-Salpetriere, University Hospital Center of Martinique |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | gait velocity | gait recordings | at inclusion | |
Secondary | brain anatomy | magnetic resonance imaging | at inclusion | |
Secondary | oculomotor movements recordings | oculomotor movements recordings | at inclusion |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02194816 -
Modifiable Variables in Parkinsonism (MVP)
|
||
Completed |
NCT00703677 -
A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal Degeneration
|
Phase 1/Phase 2 | |
Completed |
NCT00382824 -
Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP)
|
N/A | |
Completed |
NCT04184063 -
Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA)
|
Phase 2 | |
Recruiting |
NCT04706234 -
Systematic Assessment of Laryngopharyngeal Function in Patients With MSA, PD, and 4repeat Tauopathies
|
||
Recruiting |
NCT04472130 -
Neurodegenerative Diseases Registry
|
||
Recruiting |
NCT04139551 -
Oxford Study of Quantification in Parkinsonism
|
||
Completed |
NCT02734485 -
Deep TMS for the Treatment of Patients With Parkinson's Disease and Progressive Supranuclear Palsy
|
N/A | |
Completed |
NCT01110720 -
Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy
|
Phase 2/Phase 3 | |
Completed |
NCT01174771 -
Repetitive Transcranial Magnetic Stimulation (TMS) for Progressive Supranuclear Palsy and Corticobasal Degeneration
|
N/A | |
Completed |
NCT00465790 -
Research of Biomarkers in Parkinson Disease
|
Phase 0 | |
Completed |
NCT02460094 -
Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy
|
Phase 1 | |
Active, not recruiting |
NCT04993768 -
A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP)
|
Phase 2 | |
Recruiting |
NCT03225144 -
Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
|
||
Completed |
NCT03058965 -
Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain
|
Early Phase 1 | |
Recruiting |
NCT02605785 -
A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy
|
N/A | |
Completed |
NCT01353183 -
Analysis of the Enteric Nervous System Using Colonic Biopsies
|
N/A | |
Completed |
NCT00385710 -
Trial of Valproic Acid in Patients With Progressive Supranuclear Palsy (Depakine)
|
Phase 2 | |
Recruiting |
NCT05260151 -
Tau Protein and SV2a Imaging in Patients With Tau Protein-related Diseases
|
||
Active, not recruiting |
NCT04658199 -
A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy
|
Phase 1 |